Skip to main content

Table 2 Concomitant mood stabilizers

From: Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments

Mood stabilizer at baseline, n (%)

Placebo n = 199

Armodafinil 150 mg/day n = 200

Patients taking one mood stabilizer

150 (75)

158 (79)

 Aripiprazole

16 (8)

9 (5)

 Lamotrigine

26 (13)

28 (14)

 Lithium

12 (6)

18 (9)

 Olanzapine

23 (12)

25 (13)

 Quetiapine

18 (9)

26 (13)

 Risperidone

29 (15)

24 (12)

 Valproic acid

26 (13)

28 (14)

Patients taking two mood stabilizers

45 (23)

38 (19)

 Aripiprazole + lamotrigine

4 (2)

1 (<1)

 Lamotrigine + quetiapine

7 (4)

1 (<1)

 Lamotrigine + ziprasidone

1 (<1)

1 (<1)

 Lithium + aripiprazole

1 (<1)

0

 Lithium + lamotrigine

3 (2)

2 (1)

 Lithium + olanzapine

2 (1)

0

 Lithium + quetiapine

4 (2)

3 (2)

 Lithium + risperidone

1 (<1)

1 (<1)

 Lithium + valproic acid

2 (1)

1 (<1)

 Lithium + ziprasidone

3 (2)

1 (<1)

 Olanzapine + lamotrigine

1 (<1)

1 (<1)

 Olanzapine + quetiapine

1 (<1)

0

 Valproic acid + aripiprazole

0

2 (1)

 Valproic acid + lamotrigine

2 (1)

0

 Valproic acid + olanzapine

5 (3)

8 (4)

 Valproic acid + quetiapine

5 (3)

9 (5)

 Valproic acid + risperidone

3 (2)

5 (3)

 Valproic acid + ziprasidone

0

2 (1)

Patients taking three mood stabilizers

1 (<1)

3 (2)

 Lithium + lamotrigine + ziprasidone

0

1 (<1)

 Valproic acid + aripiprazole + risperidone

0

1 (<1)

 Valproic acid + olanzapine + lamotrigine

0

1 (<1)

 Valproic acid + risperidone + quetiapine

1 (<1)

0

Patients with mood stabilizer unknown

3 (2)

1 (<1)